Evidence map›Paper›PMID 31362032›Full record

ArticleRegulatory toxicology and pharmacology : RTP2019

Nonclinical safety assessment of PF614: A novel TAAP prodrug of oxycodone for chronic pain indication.

P S Joshi, N Sanakkayala, L Kirkpatrick, P S Terse

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Regulatory toxicology and pharmacology : RTP, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

P S JoshiNational Center for Advancing Translational Sciences, Bethesda, MD, United States.
N SanakkayalaCovance Laboratories, Inc., 3301 Kinsman Blvd., Madison, WI, United States.
L KirkpatrickEnsysce Biosciences Inc., San Diego, CA, United States.
P S TerseNational Center for Advancing Translational Sciences, Bethesda, MD, United States. Electronic address: tersep@mail.nih.gov.
National Center for Advancing Translational Sciences · USCovance (United States) · US

Funding

CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

PF614, a novel trypsin activated abuse protection (TAAP) prodrug of oxycodone, is being studied as chronic pain analgesic with extended release and abuse resistant properties. A series of nonclinical safety studies were conducted to support PF614 introduction to clinical trials. Ames assays (PF614 and its metabolites), comet assay (PF614 ≤ 50 mg/kg/day oral gavage in rats) and micronucleus assay (PF614 ≤ 175 mg/kg/day oral gavage in rats) were negative. hERG assay IC

Indexed as

Abuse-Deterrent FormulationsAnalgesics, OpioidAnimalsATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2Caco-2 CellsDogsElectrocardiographyFemaleHepatocytesHumansMaleMutagenicity TestsNeoplasm ProteinsOxycodoneProdrugsABCG2 protein, humanAbuse-Deterrent FormulationsAnalgesics, OpioidATP Binding Cassette Transporter, Subfamily B, Member 1ATP Binding Cassette Transporter, Subfamily G, Member 2ERG protein, humanNeoplasm ProteinsOxycodoneProdrugsTranscriptional Regulator ERGTrypsinOxycodonePF614Prodrug

Identifiers

PMID31362032
PMCPMC6790176
OpenAlexW2966781724

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.